相关实验视频

Updated: Jul 22, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

对于B细胞淋巴瘤的高级仿真抗原受体-T设计和部署的挑战和解决方案

Jenny Gao¹, Saurabh Dahiya², Shyam A Patel³

¹RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA.

British journal of haematology

|July 24, 2023

概括

化学抗原受体-T (CAR-T) 疗法对B细胞淋巴瘤有希望,但面临挑战. 本综述探讨了早期在癌症治疗中使用CAR-T的障碍和解决方案.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞疗法细胞疗法

背景情况:

化学抗原受体-T (CAR-T) 疗法是一种革命性的活体免疫疗法,利用患者的免疫系统.
卡尔-T疗法在复发/耐药B细胞淋巴瘤中取得了显著的成功.
尽管使用了十多年,但对将CAR-T整合到治疗范例中的共识指南仍然有限.

研究的目的:

讨论阻碍CAR-T产品进入早期激进淋巴瘤治疗线路的障碍.
突出克服这些障碍的潜在解决方案.
审查早期在B细胞淋巴瘤中部署CAR-T的证据,考虑到最近批准的双特异性抗体.

主要方法:

对当前文献和临床证据进行了专注的审查.
对CAR-T疗法进步障碍的分析.
评估新兴的治疗策略和最近的监管批准.

主要成果:

主要障碍包括抗原逃逸",冷"瘤微环境,宿主炎症和CAR-T细胞耗尽.
潜在的解决方案包括医疗点CAR-T制造和早期T细胞采集 (淋巴酶).
最近FDA对抗CD3/CD20双特异性抗体 (mosunetuzumab,epcoritamab,glofitamab) 的批准影响了治疗环境.

结论:

在B细胞淋巴瘤中早期部署CAR-T需要进一步调查.
解决已识别的障碍对于扩大CAR-T治疗范围至关重要.
提出了2024年的实际建议,以指导临床实践和未来的研究.

关键词:

B 细胞 B 细胞 B 细胞在CAR-T疗法中.两种特异性的抗体.淋巴瘤淋巴瘤是什么非霍奇金淋巴瘤的非霍奇金淋巴瘤.

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...